KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Net (2016 - 2025)

Alnylam Pharmaceuticals' Receivables - Net history spans 17 years, with the latest figure at $777.6 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 91.85% year-over-year to $777.6 million; the TTM value through Dec 2025 reached $777.6 million, up 91.85%, while the annual FY2025 figure was $777.6 million, 91.85% up from the prior year.
  • Receivables - Net reached $777.6 million in Q4 2025 per ALNY's latest filing, down from $964.8 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $964.8 million in Q3 2025 to a low of $9.1 million in Q2 2022.
  • Average Receivables - Net over 5 years is $309.6 million, with a median of $273.7 million recorded in 2022.
  • Peak YoY movement for Receivables - Net: crashed 74.71% in 2021, then surged 2331.51% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $198.6 million in 2021, then grew by 19.84% to $238.0 million in 2022, then skyrocketed by 37.75% to $327.8 million in 2023, then rose by 23.65% to $405.3 million in 2024, then surged by 91.85% to $777.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Receivables - Net are $777.6 million (Q4 2025), $964.8 million (Q3 2025), and $567.1 million (Q2 2025).